» Articles » PMID: 9371658

A Decay-accelerating Factor-binding Strain of Coxsackievirus B3 Requires the Coxsackievirus-adenovirus Receptor Protein to Mediate Lytic Infection of Rhabdomyosarcoma Cells

Overview
Journal J Virol
Date 1997 Nov 26
PMID 9371658
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The composition of the cellular receptor complex for coxsackievirus B3 (CVB3) has been an area of much contention for the last 30 years. Recently, two individual components of a putative CVB3 cellular receptor complex have been identified as (i) decay-accelerating factor (DAF) and (ii) the coxsackievirus-adenovirus receptor protein (CAR). The present study elucidates the individual roles of DAF and CAR in cell entry of CVB3 Nancy. First, we confirm that the DAF-binding phenotype of CVB3 correlates to the presence of key amino acids located in the viral capsid protein, VP2. Second, using antibody blockade, we show that complete protection of permissive cells from infection by high input multiplicities of CVB3 requires a combination of both anti-DAF and anti-CAR antibodies. Finally, it is shown that expression of the CAR protein on the surface of nonpermissive DAF-expressing RD cells renders them highly susceptible to CVB3-mediated lytic infection. Therefore, although the majority of CVB3 Nancy attaches to the cell via DAF, only virus directly interacting with the CAR protein mediates lytic infection. The role of DAF in CVB3 cell infection may be analogous to that recently described for coxsackievirus A21 (D. R. Shafren, D. J. Dorahy, R. A. Ingham, G. F. Burns, and R. D. Barry, J. Virol. 71:4736-4743, 1997), in that DAF may act as a CVB3 sequestration site, enhancing viral presentation to the functional CAR protein.

Citing Articles

Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.

Dong W, Luo Y, He D, Zhang M, Zeng J, Chen Y Front Immunol. 2024; 15:1473288.

PMID: 39430750 PMC: 11486668. DOI: 10.3389/fimmu.2024.1473288.


Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer.

Sakamoto A, Inoue H, Miyamoto S, Ito S, Soda Y, Tani K Sci Rep. 2023; 13(1):5924.

PMID: 37046036 PMC: 10097657. DOI: 10.1038/s41598-023-33126-x.


Vaccines against Group B Coxsackieviruses and Their Importance.

Mone K, Lasrado N, Sur M, Reddy J Vaccines (Basel). 2023; 11(2).

PMID: 36851152 PMC: 9961666. DOI: 10.3390/vaccines11020274.


Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies.

Ho H, Peischard S, Strutz-Seebohm N, Klingel K, Seebohm G Viruses. 2021; 13(9).

PMID: 34578462 PMC: 8473126. DOI: 10.3390/v13091880.


Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives.

Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M Cancers (Basel). 2021; 13(11).

PMID: 34199429 PMC: 8199618. DOI: 10.3390/cancers13112761.


References
1.
CROWELL R, Philipson L . Specific alterations of coxsackievirus B3 eluted from HeLa cells. J Virol. 1971; 8(4):509-15. PMC: 376224. DOI: 10.1128/JVI.8.4.509-515.1971. View

2.
Shafren D, Dorahy D, Ingham R, Burns G, BARRY R . Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997; 71(6):4736-43. PMC: 191695. DOI: 10.1128/JVI.71.6.4736-4743.1997. View

3.
LONBERG-HOLM K, CROWELL R, Philipson L . Unrelated animal viruses share receptors. Nature. 1976; 259(5545):679-81. DOI: 10.1038/259679a0. View

4.
Reagan K, Goldberg B, CROWELL R . Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells. J Virol. 1984; 49(3):635-40. PMC: 255518. DOI: 10.1128/JVI.49.3.635-640.1984. View

5.
Kinoshita T, Medof M, Silber R, NUSSENZWEIG V . Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1985; 162(1):75-92. PMC: 2187705. DOI: 10.1084/jem.162.1.75. View